Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Clinical trial NCT04725188 · COMPLETED

Trial details

NCT number: NCT04725188
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Non Small Cell Lung Cancer

Start date: 2021-04-20
Primary completion: 2023-01-26
Enrollment: 255

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.